Evaluation of the palliative effect of a topical emulgel containing piroxicam-entrapped nanoniosomes on patients suffering OA or RA with joint pai
Phase 2
- Conditions
- Condition 1: Osteoarthritis. Condition 2: Rheumatoid arthritis.Osteoarthritis of kneeRheumatoid arthritis with rheumatoid factor
- Registration Number
- IRCT20180526039839N1
- Lead Sponsor
- Daroo Sazan Sorena Exir Company
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Experiencing pain in one or more joint
Having acute (less than three weeks), Sub-acute (three weeks to three months) or chronic (more than three months) joint pain
Age between 18 to 80 years old
Exclusion Criteria
Consumption of oral, rectal, or parenteral pain killers or anti-inflammation drugs including corticosteroids, NSAIDs, acetaminophen, narcotics, Herbal pain killers with scientifically-proven effect
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Joint pain in rest and during movement. Timepoint: The pain levels will be recorded daily from the first to the seventh day of initiating the clinical trial. Method of measurement: The pain level will be measured using numerical rating scale.
- Secondary Outcome Measures
Name Time Method